Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis

https://doi.org/10.1016/0091-6749(93)90076-RGet rights and content

Abstract

Background: Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate for efficacy and safety in the treatment of systemic mastocytosis.

Methods: Fifteen subjects with mastocytosis participated in a double-blind, randomized, three-period, crossover trial, which compared an azelastine regimen of 4 mg or 8 mg every 12 hours with a chlorpheniramine regimen of 12 mg every 12 hours. Response to therapy was assessed by daily symptom scores, extinction dilution skin tests, plasma histamine levels, and global evaluations.

Results: Subjects' mean wheal area responses provoked by histamine or morphine sulfate were significantly lowered by azelastine when compared with chlorpheniramine. Plasma histamine levels in subjects receiving azelastine or chlorpheniramine were not significantly different. There were no significant differences between azelastine and chlorpheniramine in individual symptom scores or global evaluations except that azelastine at both doses significantly relieved pruritus and at 4 mg significantly relieved abdominal pain and that chlorpheniramine was associated with less fatigue in comparison to azelastine at 8 mg.

Conclusions: It thus appears that azelastine is superior to chlorpheniramine in suppressing skin responses to histamine and morphine sulfate and in suppressing pruritus in patients with mastocytosis. However, when all parameters are considered, neither drug is clearly superior for the treatment of patients with mastocytosis.

Cited by (38)

  • The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome

    2020, Journal of Allergy and Clinical Immunology: In Practice
    Citation Excerpt :

    N-MH excretion also correlated with serum tryptase values.105 Treatment of symptoms in SM with antihistamines has shown approximately equal effectiveness of azelastine and chlorpheniramine, though azelastine was superior to chlorpheniramine in suppressing skin responses to histamine and morphine sulfate and in suppressing pruritus.106 Control of SM symptoms with cromolyn sodium or the combination of chlorpheniramine and cimetidine is approximately equal.107

  • Antihistamines

    2020, Comprehensive Dermatologic Drug Therapy, Fourth Edition
  • Gastrointestinal Involvement in Mast Cell Activation Disorders

    2018, Immunology and Allergy Clinics of North America
    Citation Excerpt :

    In addition to being an H1 blocker, ketotifen and desloratadine may also decrease mast cell mediator release, although ketotifen has not been shown to be superior to traditional H1 antagonists in mastocytosis.48–50 It may be the H2 antagonists that provide the most GI symptom relief in systemic mastocytosis; although some earlier studies have suggested that H1 antagonists may improve GI symptoms, a more recent double-blind, placebo-controlled study of the second-generation dual H1 receptor/platelet activating factor antagonist rupatadine in adult mastocytosis subjects found statistically significant improvement in the treatment group for a large number of clinical symptom parameters except for GI symptoms.50–53 Abdominal cramping and diarrhea may be responsive to oral cromolyn sodium.54

  • Anti-H1 in dermatological practice

    2005, Annales de Dermatologie et de Venereologie
View all citing articles on Scopus
View full text